Market Cap | 8.64M | P/E | 1.09 | EPS this Y | - | Ern Qtrly Grth | - |
Income | -1.24M | Forward P/E | -1.09 | EPS next Y | - | 50D Avg Chg | -17.00% |
Sales | 70k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -54.00% |
Dividend | N/A | Price/Book | 0.45 | EPS next 5Y | - | 52W High Chg | -80.00% |
Recommedations | 2.00 | Quick Ratio | 0.01 | Shares Outstanding | 406.27M | 52W Low Chg | 118.00% |
Insider Own | 54.06% | ROA | -0.76% | Shares Float | 186.63M | Beta | -0.21 |
Inst Own | - | ROE | -12.83% | Shares Shorted/Prior | 662.75K/812.77K | Price | 0.02 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 318,201 | Target Price | - |
Oper. Margin | -518.27% | Earnings Date | Nov 12 | Volume | 67,966 | Change | -12.10% |
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it is developing CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies. The company is headquartered in Agoura Hills, California.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Trieu Vuong | CHAIRMAN AND CEO CHAIRMAN AND CEO | Jun 14 | Buy | 0.0326 | 400,000 | 13,040 | 91,444,217 | 06/16/23 |
Trieu Vuong | CHAIRMAN AND CEO CHAIRMAN AND CEO | May 26 | Buy | 0.0341 | 126,888 | 4,327 | 91,044,217 | 05/31/23 |
Trieu Vuong | CHAIRMAN AND CEO CHAIRMAN AND CEO | Dec 06 | Buy | 0.05 | 120,000 | 6,000 | 90,558,021 | 12/07/22 |
Trieu Vuong | CHAIRMAN AND CEO CHAIRMAN AND CEO | Sep 26 | Buy | 0.068 | 20,000 | 1,360 | 90,368,021 | 09/28/22 |
Trieu Vuong | CHAIRMAN AND CEO CHAIRMAN AND CEO | Aug 25 | Buy | 0.082 | 80,000 | 6,560 | 90,348,021 | 08/29/22 |